Deal Announcement

Fortlane Partners advised Armira

Fortlane Partners advised Armira on the refinancing of its portfolio asset Scheu-Dental with a Commercial Review 

Due Diligence
Healthcare and Life Sciences
Reading Time 2 Minutes
Transaction
May 2025
Icon: flag-DEIcon: flag-DE

Fortlane Partners advised

Armira with a

Commercial Review

on the refinancing of its portfolio asset Scheu-Dental

Value not disclosed

Fortlane Partners advised Armira on the refinancing of its portfolio asset Scheu-Dental GmbH (“Scheu-Dental”), a globally leading full-service manufacturer and distributor of dental and orthodontic equipment serving orthodontists, dentists, and dental laboratories, through a Commercial Review.

The Commercial Review comprised a thorough analysis of the company’s product portfolio and underlying business model, with a particular focus on identifying and evaluating Scheu-Dental’s unique selling proposition. In parallel, Fortlane Partners conducted a market sizing exercise and analyzed growth dynamics across the company’s core target segments. The review also included a detailed benchmarking of Scheu-Dental’s competitive positioning within the broader dental and orthodontic landscape. Based on these insights, the team assessed the robustness of the company’s business plan and evaluated the commercial potential of an innovative aligner treatment concept developed by Scheu-Dental.

This engagement reinforces Fortlane Partners’ strong track record in delivering strategic and commercial advisory services within the healthcare sector.

About Scheu-Dental
Scheu-Dental is a globally leading full-service manufacturer and distributor of dental and orthodontic equipment addressing the needs of orthodontists, dentists, and laboratories. The company offers a comprehensive product portfolio, including molding devices, foils, 3D printers, orthodontic equipment, as well as aligner and retainer production solutions (including software) covering various dental treatments like misalignment correction, stabilization, and protection as well as treatment of snoring and sleep apnea.

 

Transaction team:

Dr. Gerrit Schütte
Managing Director
Email

Gerrit Bückins
Principal

Jannis Sandow
Senior Consultant 

Contact

Dr. Gerrit Schütte
Dr. Gerrit Schütte
Managing Director
Due Diligence, Value Creation and Exit Readiness, Portfolio Strategy and Buy & Build, Principal Investors and Private Equity, Industrials and Automotive